O-GlcNAcylation in cellular senescence: From molecular insights to anti-cancer therapeutic opportunities
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189665
DOI: 10.1016/j.bbcan.2026.189665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Adrien Pioger und 3 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Inserm, Institut Pasteur de Lille, CHU Lille, UMR9020-U1366 - CRCLille - Cancer Research Center of Lille, F-59000 Lille, France. Hauptthemen laut MEDLINE: Cellular Senescence, Neoplasms, Acetylglucosamine. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National League Against Cancer, National Federation of French Business Groups in the Fight Against Cancer, Hauts-de-France Region.
Abstract (Originalsprache)
Cellular senescence is a dynamic stress response with broad implications in aging, tissue homeostasis, and disease. In anti-cancer therapies, senescence acts as a double-edged sword, initially suppressing tumor growth but contributing to therapy tolerance and minimal residual disease, later leading to tumor repopulation, and relapse. While senescent cells are the seat of a large-scale metabolic reprogramming, the specific contribution of O-GlcNAcylation, a nutrient-sensitive post-translational modification involved in cancer progression and therapy resistance, was only recently investigated. Here, we first summarize studies reporting changes in O-GlcNAcylation levels during senescence and how modulation of O-GlcNAc cycling enzymes influences senescence onset, maintenance, and escape. We then discuss evidence suggesting that O-GlcNAcylation may influence several hallmarks of senescence, including cell cycle arrest, DNA damage response, apoptosis resistance, metabolic rewiring and mitochondrial stress signaling. Finally, we discuss the potential therapeutic relevance of targeting O-GlcNAc cycling enzymes to modulate cancer cell senescence, limit senescence escape, and thereby improve anti-cancer treatment responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Lille, CNRS, Inserm, Institut Pasteur de Lille, CHU Lille, UMR9020-U1366 - CRCLille - Cancer Research Center of Lille, F-59000 Lille, France.
- Univ. Lille, CNRS, Inserm, Institut Pasteur de Lille, CHU Lille, UMR9020-U1366 - CRCLille - Cancer Research Center of Lille, F-59000 Lille, France. Electronic address: vanessa.dehennaut@univ-lille.fr.
Förderung
- National League Against Cancer
- National Federation of French Business Groups in the Fight Against Cancer
- Hauts-de-France Region
Zitieren
APA
Pioger, A., Martin, N., Abbadie, C., & Dehennaut, V. (2026). O-GlcNAcylation in cellular senescence: From molecular insights to anti-cancer therapeutic opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189665. https://doi.org/10.1016/j.bbcan.2026.189665
Vancouver
Pioger A, Martin N, Abbadie C, Dehennaut V. O-GlcNAcylation in cellular senescence: From molecular insights to anti-cancer therapeutic opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189665. doi:10.1016/j.bbcan.2026.189665
BibTeX
@article{Pioger2026,
author = {Pioger, Adrien and Martin, Nathalie and Abbadie, Corinne and Dehennaut, Vanessa},
title = {O-GlcNAcylation in cellular senescence: From molecular insights to anti-cancer therapeutic opportunities},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189665},
doi = {10.1016/j.bbcan.2026.189665}
}
EUVIMED